ERBB2 and breast carcinoma: The introduction of anti-HER2 agents has changed the paradigm of HER2-positive breast cancer treatment in the last 2 decades, with monoclonal antibodies, tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) now being the backbone of HER2-positive MBC treatment [19].